EHA 2019 Conference Review - focus on MM and Lymphoma, reviewed by Associate Professor Philip Campbe

In this review:

VTD ±daratumumab in transplant-eligible newly diagnosed MM
Fixed-duration venetoclax + obinutuzumab in previously untreated CLL
Treatment dependence of high-risk de novo follicular lymphoma
Polatuzumab/obinutuzumab/lenalidomide in relapsed/refractory follicular lymphoma
Subcutaneous vs. intravenous daratumumab in relapsed/refractory MM
Pomalidomide/dexamethasone ±isatuximab in relapsed/refractory MM
Three PRM-151 doses in myelofibrosis
Ibrutinib in asymptomatic, treatment-naïve, early-stage CLL
Acalabrutinib vs. rituximab + idelalisib/ bendamustine in relapsed/refractory CLL
Blinatumomab for MRD in B-cell precursor ALL: final OS analysis for BLAST

Please login below to download this issue (PDF)